📰 Clin Pract News

Clin Pract News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Clin Pract. Real-time updates on events, politics, business and more.

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

April 24, 2024

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a...

United States Comunidad Autonoma De Cataluna Antonio Alcaraz Ahsan Arozullah European Union Drug Administration

Source: prnewswire.com

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting

November 17, 2023

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the companies...

United States Chris Boshoff Naoki Okamura Ahsan Arozullah Courtney Bugler Head Of Oncology Development

Source: prnewswire.com

European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

September 12, 2023

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the European Medicines Agency (EMA) has...

United States Ahsan Arozullah Naoki Okamura Medivation Inc Drug Administration European Union

Source: prnewswire.com

FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

August 23, 2023

/PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food...

United States Chris Boshoff Ahsan Arozullah Naoki Okamura Prnewswire Pfizer Inc Astellas Inc

Source: prnewswire.com

Neurologic Events After COVID-19 Vaccines Assessed

May 26, 2023

Study finds preexisting risk factors in all patients hospitalized for neurologic symptoms

New York United States Kiran Thakur Judy George Columbia University Irving Medical Center Newyork Columbia University Irving Medical

Source: medpagetoday.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

April 29, 2023

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) announced today that XTANDI®...

United States Naoki Okamura Exchange Commission Medivation Inc Lab Abnormalities European Union

Source: prnewswire.com

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer

March 23, 2023

Pfizer and Astellas announce positive top-line results from Phase 3 EMBARK trial MARKHAM, ON, March 23, 2023 /CNW/ - Astellas Pharma Inc. , the parent company of Astellas Pharma Canada, Inc., has... | March 23, 2023

United States Chris Boshoff Kenji Yasukawa Ahsan Arozullah Astellas Pharma Inc American Society Of Clinical Oncology

Source: marketscreener.com

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

March 17, 2023

/PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive...

United States Kenji Yasukawa Chris Boshoff Ahsan Arozullah American Society Of Clinical Oncology Prnewswire Pfizer Inc

Source: prnewswire.com